#Hyperdiploidy
MM 的標準風險細胞遺傳學
Hyperdiploidy(預後最佳)、t(11;14)、t(6;14)。
高風險:t(4;14)、t(14;16)、t(14;20) 三個 IGH 易位,加上 del(17p13)。
記法:14 兩兩相配的 4/16/20,再加一個 17p 掉了。
近年再納入 gain/amp(1q21)、del(1p32) 與 TP53 突變;≥2 項稱 double-hit。
#血液專科
https://hema-2026.hsiehting.com/q/111-046
August 4, 2026 at 3:51 AM
R-ISS 的高風險三兄弟
del(17p)、t(4;14)、t(14;16) —— 任一即為高風險細胞遺傳學。
R-ISS 在傳統 ISS(β2-microglobulin、albumin)之上,加入這三項與血清 LDH。
對照組:t(11;14) 與 hyperdiploidy 屬標準或較佳風險。
#血液專科
https://hema-2026.hsiehting.com/q/112-065
August 3, 2026 at 5:30 PM
B-ALL 分子亞型的預後分層
良好:ETV6::RUNX1〔t(12;21)〕、DUX4-r(即使合併 IKZF1 缺失)、hyperdiploidy(尤其 trisomy 4、10、17)。
高風險:MEF2D-r、TCF3::HLF、BCR::ABL1-like、hypodiploidy、KMT2A-r。
#血液專科
https://hema-2026.hsiehting.com/q/114-014
August 3, 2026 at 7:39 AM
🩸Facts about Multiple Myeloma:

Myeloma Biology and Microenvironment

#MultipleMyeloma #Hematology #NKcells #Cytogenetics #HEMEHUB #TP53 #NFkB #Hyperdiploidy #t1114 #del17p #HemOnc #MedEd
February 24, 2026 at 6:08 PM
🩸 Today’s question focuses on cytogenetic features and long-term survival in multiple myeloma.

See the answer and explanation on the next slide!

#MultipleMyeloma #Cytogenetics #Hyperdiploidy #LongTermSurvival #Hematology #HemeOnc #Cancer #MedEd
February 11, 2026 at 7:55 PM
Interesting study by the Munshi group at DFCI. Whole genome sequences of 72 hyperdiploid myeloma patients, tracing back the early origins of hyperdiploidy and mapping additional mutations. ashpublications.org/blood/articl... #hemesky #myelomasky 🔬🩸
ashpublications.org
November 23, 2024 at 8:18 AM
RRIDs were included in this in Cell Reports paper. We value the author's support of reproducibility. #OpenResearch #STMpublishing #BetterScience
Hyperdiploidy impairs fetal hematopoietic progenitor fitness and differentiation enabling persistence of rare preleukemic aneuploid clones
Read the full paper: Hyperdiploidy impairs fetal hematopoietic progenitor fitness and differentiation enabling persistence of rare preleukemic aneuploid clones
doi.org
April 1, 2026 at 7:01 AM
DLKP‑M is a mesenchymal‑like clonal variant of the DLKP lung carcinoma line, representing ~5% of the parental population. It shows hyperdiploidy, rapid ECM attachment, and neuroendocrine marker expression. More info: https://bit.ly/4qVr571
#ECACC #CultureCollections
February 26, 2026 at 4:47 PM
Extra chromosomes in blood cells can create rare, long-lived clones in bone marrow years before childhood leukemia develops, highlighting a potential early window for intervention. doi.org/hbwd5r
Extra chromosomes may seed childhood leukemia years before disease, study suggests
B-cell acute lymphoblastic leukemia is the most common form of childhood cancer. In this type of cancer, which affects blood cells, one of the most common abnormalities is the presence of cells with an excess of chromosomes (hyperdiploidy), a condition that leads to chromosomal instability.
medicalxpress.com
April 8, 2026 at 7:20 PM
The referenced paper here..to point below. Very interesting.

ashpublications.org/blood/articl...
November 27, 2024 at 12:30 AM
ICYMI: Hyperdiploidy in AML: A Case Report and Review of the Literature
Hyperdiploidy in AML: A Case Report and Review of the Literature
Acute myeloid leukemia (AML) is a heterogeneous disease, indicated by its many conceivable cytogenetic mutations. Hyperdiploidy is a rare abnormality in AML, more prevalent in children than adults, with few other distinguishing associations...
eurekamag.com
October 21, 2025 at 7:43 AM
Hyperdiploidy in AML: A Case Report and Review of the Literature
Hyperdiploidy in AML: A Case Report and Review of the Literature
Acute myeloid leukemia (AML) is a heterogeneous disease, indicated by its many conceivable cytogenetic mutations. Hyperdiploidy is a rare abnormality in AML, more prevalent in children than adults, with few other distinguishing associations...
eurekamag.com
October 20, 2025 at 7:42 AM
🔊First-line zanubrutinib, obinutuzumab, and venetoclax in mantle cell lymphoma; hyperdiploidy in multiple myeloma; and pegcrisantaspase plus venetoclax in relapsed/refractory acute myeloid leukemia 🎧https://buff.ly/4jxtgLH #bloodjournals
buff.ly
February 5, 2025 at 4:00 PM
🔊First-line zanubrutinib, obinutuzumab, and venetoclax in mantle cell lymphoma; hyperdiploidy in multiple myeloma; and pegcrisantaspase plus venetoclax in relapsed/refractory acute myeloid leukemia 🎧https://buff.ly/4jxtgLH #bloodjournals
buff.ly
February 4, 2025 at 1:00 PM
🔊First-line zanubrutinib, obinutuzumab, and venetoclax in mantle cell lymphoma; hyperdiploidy in multiple myeloma; and pegcrisantaspase plus venetoclax in relapsed/refractory acute myeloid leukemia 🎧https://buff.ly/4hgy1rk #bloodjournals
February 1, 2025 at 5:00 PM
🔊First-line zanubrutinib, obinutuzumab, and venetoclax in mantle cell lymphoma; hyperdiploidy in multiple myeloma; and pegcrisantaspase plus venetoclax in relapsed/refractory acute myeloid leukemia 🎧https://buff.ly/4hgy1rk #bloodjournals
January 31, 2025 at 2:00 PM
Hyperdiploidy impairs fetal hematopoietic progenitor fitness and differentiation enabling persistence of rare preleukemic aneuploid clones
Hyperdiploidy impairs fetal hematopoietic progenitor fitness and differentiation enabling persistence of rare preleukemic aneuploid clones
Thampi et al. model prenatal hyperdiploidy in human fetal hematopoietic stem/progenitor cells and show that aneuploidy impairs fitness and delays differentiation. Although hyperdiploid cells are outcompeted in vitro, rare clones persist in vivo with cB-ALL-like chromosomal gains but fail to initiate leukemia, supporting a two-step leukemogenesis model.
dlvr.it
April 17, 2026 at 12:35 PM